Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 11 11 2019
accepted: 07 01 2020
entrez: 3 3 2020
pubmed: 3 3 2020
medline: 20 2 2021
Statut: epublish

Résumé

Graft-vs.-host disease (GvHD) is a major complication after allogeneic hematopoietic stem cell transplantation that causes mortality and severe morbidity. Genetic disparities in human leukocyte antigens between the recipient and donor are known contributors to the risk of the disease. However, the overall impact of genetic component is complex, and consistent findings across different populations and studies remain sparse. To gain a comprehensive understanding of the genes responsible for GvHD, we combined genome-wide association studies (GWAS) from two distinct populations with previously published gene expression studies on GvHD in a single gene-level meta-analysis. We hypothesized that genes driving GvHD should be associated in both data modalities and therefore could be detected more readily through their combined effects in the integrated analysis rather than in separate analyses. The meta-analysis yielded a total of 51 acute GvHD-associated genes (false detection rate [FDR] <0.1). In support of our hypothesis, this number was significantly higher than that in a permutation meta-analysis involving the whole data set, as well as in separate meta-analyses on the GWAS and gene expression data sets. The genes indicated by the meta-analysis were significantly enriched in 277 Gene Ontology terms (FDR < 0.05), such as T cell function and cytokine-mediated signaling pathways, and the results highlighted several established immune mediators, such as interleukins and JAK-STAT signaling, and presented TRAF6 and TERT as potential effector candidates. Altogether, the results support the chosen methodological approach, implicate a role of gene-level variation in donors' key immunological regulators predisposing patients to acute GVHD, and present potential targets for therapeutic intervention.

Identifiants

pubmed: 32117222
doi: 10.3389/fimmu.2020.00019
pmc: PMC7008714
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19

Informations de copyright

Copyright © 2020 Hyvärinen, Koskela, Niittyvuopio, Nihtinen, Volin, Salmenniemi, Putkonen, Buño, Gallardo, Itälä-Remes, Partanen and Ritari.

Références

Exp Hematol. 2008 Dec;36(12):1760-1770
pubmed: 18814951
Blood. 2005 Jan 15;105(2):894-901
pubmed: 15374888
Nature. 2006 Jan 12;439(7073):204-7
pubmed: 16306937
Biol Blood Marrow Transplant. 2019 Jun;25(6):1260-1268
pubmed: 30710687
Bone Marrow Transplant. 2018 Apr;53(4):377-382
pubmed: 29330404
Oncogene. 2001 Oct 1;20(44):6482-91
pubmed: 11607847
Nat Genet. 2009 Dec;41(12):1341-4
pubmed: 19935662
Nat Rev Immunol. 2012 May 11;12(6):443-58
pubmed: 22576252
Am J Clin Nutr. 2007 Nov;86(5):1420-5
pubmed: 17991655
Cell Immunol. 2011;268(1):37-46
pubmed: 21376308
Nat Genet. 2016 Mar;48(3):245-52
pubmed: 26854917
Leukemia. 2015 Oct;29(10):2062-8
pubmed: 26228813
Bone Marrow Transplant. 2019 Jun;54(6):810-820
pubmed: 30401967
Cell Death Dis. 2018 Sep 11;9(9):921
pubmed: 30206205
PLoS Comput Biol. 2015 Apr 17;11(4):e1004219
pubmed: 25885710
Sci Rep. 2015 Jun 11;5:11098
pubmed: 26067905
Blood. 2012 May 31;119(22):5311-9
pubmed: 22282500
Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53
pubmed: 23756210
Clin Cancer Res. 2019 Aug 1;25(15):4616-4623
pubmed: 31043390
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):E4662-70
pubmed: 27462110
Cell Transplant. 2008;17(5):489-94
pubmed: 18714668
Sci Transl Med. 2015 Nov 25;7(315):315ra191
pubmed: 26606970
Blood. 2017 Feb 9;129(6):791-798
pubmed: 27872059
Arthritis Rheum. 2009 Apr;60(4):1065-75
pubmed: 19333922
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Blood. 2009 Sep 10;114(11):2236-43
pubmed: 19561322
Sci Rep. 2017 Nov 15;7(1):15666
pubmed: 29142307
Blood. 2015 Feb 12;125(7):1189-97
pubmed: 25519752
Blood. 2013 Oct 31;122(18):3220-9
pubmed: 24046013
Blood. 2012 Oct 4;120(14):2796-806
pubmed: 22859606
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
PLoS One. 2016 Oct 26;11(10):e0163998
pubmed: 27783703
J Immunol. 2016 Nov 1;197(9):3490-3503
pubmed: 27694491
J Clin Invest. 1998 Jul 1;102(1):115-23
pubmed: 9649564
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
Biol Blood Marrow Transplant. 2016 Feb;22(2):268-276
pubmed: 26325438
PLoS Med. 2007 Jan;4(1):e23
pubmed: 17378698
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Front Immunol. 2019 Jul 16;10:1625
pubmed: 31379830
Bioinformatics. 2012 Feb 15;28(4):573-80
pubmed: 22247279
Biol Blood Marrow Transplant. 2013 Feb;19(2):274-82
pubmed: 23022467
Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3921-6
pubmed: 15001702
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
Blood. 2017 Jan 5;129(1):30-37
pubmed: 27821503
Leukemia. 2019 Jan;33(1):240-248
pubmed: 30089915
Nat Protoc. 2010 Sep;5(9):1564-73
pubmed: 21085122
Bone Marrow Transplant. 2017 Jan;52(1):95-100
pubmed: 27595289
Blood. 2015 Dec 17;126(25):2752-63
pubmed: 26432889
Anticancer Res. 2017 Apr;37(4):1547-1555
pubmed: 28373413
PLoS One. 2011;6(7):e21800
pubmed: 21789182
Arch Biochem Biophys. 2000 Feb 15;374(2):334-8
pubmed: 10666315
Blood. 2012 Jun 28;119(26):6365-72
pubmed: 22586180
Blood. 2016 Sep 8;128(10):1424-35
pubmed: 27485827
Bone Marrow Transplant. 2014 Feb;49(2):241-7
pubmed: 24121213
Nat Genet. 2019 May;51(5):768-769
pubmed: 31043754
Nat Rev Genet. 2010 Jul;11(7):499-511
pubmed: 20517342
Thorax. 2018 May;73(5):489-492
pubmed: 29382801
Front Immunol. 2016 Mar 08;7:56
pubmed: 27014257
Front Immunol. 2017 Apr 03;8:380
pubmed: 28421078
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
J Exp Med. 2016 Aug 22;213(9):1881-900
pubmed: 27526711
Clin Cancer Res. 2015 Aug 15;21(16):3740-9
pubmed: 25977345
Exp Hematol. 2016 Sep;44(9):811-816.e3
pubmed: 27321893
Blood. 2014 Oct 16;124(16):2586-95
pubmed: 25205119
Clin Immunol. 2013 Jul;148(1):124-35
pubmed: 23685278
Eur J Immunol. 2018 Dec;48(12):1944-1957
pubmed: 30365157

Auteurs

Kati Hyvärinen (K)

Finnish Red Cross Blood Service, Helsinki, Finland.

Satu Koskela (S)

Finnish Red Cross Blood Service, Helsinki, Finland.

Riitta Niittyvuopio (R)

Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.

Anne Nihtinen (A)

Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.

Liisa Volin (L)

Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.

Urpu Salmenniemi (U)

Turku University Hospital, Turku, Finland.

Mervi Putkonen (M)

Turku University Hospital, Turku, Finland.

Ismael Buño (I)

Department of Hematology, Genomics Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.

David Gallardo (D)

Department of Hematology, Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.

Maija Itälä-Remes (M)

Turku University Hospital, Turku, Finland.

Jukka Partanen (J)

Finnish Red Cross Blood Service, Helsinki, Finland.

Jarmo Ritari (J)

Finnish Red Cross Blood Service, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH